This webinar is a livestream of the Institute’s pre-ESMO symposium in Madrid and is a non-commercial event open to the public at no cost. Attendance at ESMO is not required. This discussion is designed for a broad oncology audience and will provide relevant insights for patients, clinicians, healthcare providers, non-profits, health economists, and professionals across the pharmaceutical and life sciences sectors.

Phase I oncology trials are evolving rapidly, driven by advances in precision medicine, immunotherapy, and cell and gene therapies. At the same time, China is emerging as a major hub for early oncology development, reshaping global research and regulatory strategies.

This multi-stakeholder symposium will examine how Phase I trials can generate stronger evidence, improve decision-making, and deliver greater value across the oncology development continuum. Topics include:

• The evolving role of Phase I trials: Beyond safety to dose optimization, biomarker-driven development, and early efficacy signals.
• Global shifts in oncology innovation: The impact of China’s growing role and increasingly global development strategies.
• Execution under increasing complexity: Balancing speed, scientific advancement, operational demands, and patient value.